Clinical Trials on FLT3 Expressing Hematological Malignancies in Chile

Total 3 results

Sanofi

Completed

Phase 1/2 Dose Escalation and Efficacy Study of Anti-CD38 Monoclonal Antibody in Patients With Selected CD38+ Hematological Malignancies

Hematological Malignancy

Greece, Spain, Peru, Israel, United States, Argentina, Belgium, Brazil, Chile, Finland, France, Italy, Mexico, Russian Federation, Turkey, Ukraine, United Kingdom
Merck Sharp & Dohme LLC

Active, not recruiting

A Study of Pembrolizumab/Vibostolimab (MK-7684A) in Relapsed/Refractory Hematological Malignancies (MK-7684A-004, KEYVIBE-004)

Hematological Malignancies

United States, Canada, Brazil, Chile, Denmark, France, Germany, Hungary, Israel, Italy, Poland, Russian Federation, Spain, Taiwan, Turkey, Ukraine
Merck Sharp & Dohme LLC

Recruiting

Long-term Safety and Efficacy Extension Study for Participants With Advanced Tumors Who Are Currently on Treatment or in Follow-up in a Pembrolizumab (MK-3475) Study (MK-3475-587/KEYNOTE-587)

Solid Tumors | Hematologic Malignancies

United States, Poland, Brazil, Ukraine, Argentina, Australia, Austria, Belgium, Canada, Chile, China, Colombia, Czechia, Denmark, Estonia, Finland, France, Germany, Greece, Guatemala, Hong Kong, Hungary, Israel, Italy, Japan, Korea, Republic... and more

3

Subscribe